The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Tolerability could decide first-line therapy in EGFRm disease.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
